Immunovant (IMVT) analyst forecast and price target
Analyst forecast
Consensus of 17 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| JP Morgan | Maintained | Overweight | $50.00 from $47.00 | Aug 4, 2026 |
| Citigroup | Maintained | Buy | $61.00 from $57.00 | Jun 30, 2026 |
| Guggenheim | Maintained | Buy | $62.00 from $44.00 | May 26, 2026 |
| Truist Securities | Maintained | Hold | $30.00 from $23.00 | May 22, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $40.00 from $35.00 | May 21, 2026 |
| B of A Securities | Maintained | Buy | $43.00 from $32.00 | May 21, 2026 |
| Goldman Sachs | Maintained | Neutral | $32.00 from $29.00 | Apr 15, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $35.00 | Feb 10, 2026 |
| Guggenheim | Maintained | Buy | $44.00 from $41.00 | Feb 9, 2026 |
| Truist Securities | Maintained | Hold | $22.00 from $16.00 | Jan 8, 2026 |
| Wolfe Research | Upgraded | Peer Perform → Outperform | $50.00 | Jan 6, 2026 |
| Goldman Sachs | Maintained | Neutral | $28.00 from $18.00 | Dec 15, 2025 |
| Truist Securities | Initiated Coverage | Hold | $16.00 | Oct 14, 2025 |
| JP Morgan | Maintained | Overweight | $33.00 from $37.00 | Sep 30, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $35.00 | Sep 4, 2025 |
| B of A Securities | Maintained | Buy | $30.00 from $33.00 | Aug 12, 2025 |
| JP Morgan | Maintained | Overweight | $37.00 from $40.00 | Aug 12, 2025 |
| UBS | Maintained | Neutral | $18.00 from $17.00 | Jul 28, 2025 |
| UBS | Downgraded | Buy → Neutral | $17.00 from $38.00 | Apr 22, 2025 |
| B of A Securities | Maintained | Buy | $33.00 from $38.00 | Mar 20, 2025 |
Frequently asked questions
Is IMVT a buy, sell, or hold?
Analysts covering Immunovant currently average a Buy rating: 13 buy, 4 hold and 0 sell, from 17 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on IMVT?
On Aug 4, 2026, JP Morgan maintained Immunovant at Overweight with a price target of $50.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.